Covered recipient · General Payments record
ROBERT A WATSON
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$3,889.48
- Reported across 284 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $607.41 | 37 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $302.92 | 21 |
| Lilly USA, LLC | $73.99 | 5 |
| Antares Pharma, Inc. | $56.12 | 3 |
| ABIOMED | $44.00 | 1 |
| Novo Nordisk AS | $41.52 | 2 |
| Amgen Inc. | $32.52 | 2 |
| Astellas Pharma US Inc | $19.59 | 1 |
| ITI, Inc. | $19.44 | 1 |
| Acerta Pharma LLC | $17.31 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (37)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $24.10 | 01/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313441 | CMS |
| ABBVIE INC. | $9.52 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313443 | CMS |
| ABBVIE INC. | $7.27 | 01/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313445 | CMS |
| ABBVIE INC. | $18.32 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313447 | CMS |
| ABBVIE INC. | $18.68 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313449 | CMS |
| ABBVIE INC. | $17.66 | 04/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313451 | CMS |
| ABBVIE INC. | $3.36 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313453 | CMS |
| ABBVIE INC. | $8.83 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313455 | CMS |
| ABBVIE INC. | $25.36 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313457 | CMS |
| ABBVIE INC. | $1.99 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313459 | CMS |
| ABBVIE INC. | $13.49 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313461 | CMS |
| ABBVIE INC. | $2.00 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313463 | CMS |
| ABBVIE INC. | $16.16 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313465 | CMS |
| ABBVIE INC. | $31.03 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313467 | CMS |
| ABBVIE INC. | $28.09 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313469 | CMS |
| ABBVIE INC. | $4.94 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313471 | CMS |
| ABBVIE INC. | $29.68 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313473 | CMS |
| ABBVIE INC. | $10.42 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313475 | CMS |
| ABBVIE INC. | $4.49 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313477 | CMS |
| ABBVIE INC. | $6.59 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313479 | CMS |
| ABBVIE INC. | $20.94 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106313481 | CMS |
| ABIOMED | $44.00 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142307724 | CMS |
| Amgen Inc. | $14.24 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117714302 | CMS |
| Amgen Inc. | $18.28 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117714304 | CMS |
| Antares Pharma, Inc. | $18.93 | 02/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146491923 | CMS |
| Antares Pharma, Inc. | $20.68 | 09/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146491927 | CMS |
| Antares Pharma, Inc. | $16.51 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146491931 | CMS |
| Astellas Pharma US Inc | $19.59 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139363859 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.31 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104591494 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.44 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143342998 | CMS |
| Lilly USA, LLC | $14.90 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135335918 | CMS |
| Lilly USA, LLC | $14.90 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135380170 | CMS |
| Lilly USA, LLC | $13.55 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135370074 | CMS |
| Lilly USA, LLC | $15.32 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135370076 | CMS |
| Lilly USA, LLC | $15.32 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135392781 | CMS |
| Novo Nordisk Inc | $22.12 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097421660 | CMS |
| Novo Nordisk Inc | $19.40 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097743611 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.